BGI Genomics announces that its 2019-nCoV Ag Test (Latex Chromatography Assay) has recently been included in the Australian Register of Therapeutic Goods (ARTG). Therapeutic goods entered in the ARTG can be lawfully supplied in Australia.

The test kit is designed for detecting SARS CoV-2 nucleocapsid protein antigen for individuals suspected to have contracted COVID-19. The test is available at the point of care for trained health professionals (nasopharyngeal swabs), and for self-testing by laypersons (nasal swabs).

The test solution can assist in diagnosing symptomatic individuals within the first seven days of symptom onset. Self-testing can be easily conducted at home, at schools, at work, etc. It will provide reliable and quick results in 15-30 minutes.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.